CAPR - MCAP CO - Capricor Therapeutics

Capricor Therapeutics (CAPR) develops innovative cell-based therapies for heart and muscle pathologies. The stock price history reflects the company's commitment to ESG principles and bioethics regarding waste disposal. Current market capitalization stands at 0.49. The business relies on a narrow drug development profile for Duchenne muscular dystrophy, which creates high risks. However, a focus on pediatrics ensures stable demand and government support.

Capricor Therapeutics (CAPR) focuses on the development of cell-based therapies and lacks stable operating income. Market capitalization is calculated as the product of the total number of outstanding shares and their current quote. This metric assesses the aggregate value of the business in the eyes of the market. It helps investors determine the degree of overvaluation of a speculative asset. By analyzing the market capitalization of a public company, one can manage the risks of deep capital drawdowns.